Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Mar 11, 2021 · 10-K · 70 days after period end · 0001493152-21-005814
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $355.00K | $1.24M | $758.00K | $945.00K |
| Net Income | $2.03M | -$4.48M | -$44.95M | -$71.93M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 11, 2021 · 70 d after period end
